Drug · DIN 02520737
BAMBEVI
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since November 9, 2021; first marketed November 9, 2021.
- Drug Identification Number (DIN)
- 02520737
- Company (DIN owner)
- Apotex Inc.Toronto, Ontario, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Bevacizumab L01FG01
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BEVACIZUMAB | 400 MG | 16 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 23, 2021: NOC 27105New Drug Submission (NDS)
Other DINs named BAMBEVI
- DIN 02520729 · Marketed